Journal article
Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer
Abstract
BACKGROUND: Promising data have suggested that retinoid chemoprevention may help to control second primary tumors (SPTs), recurrence, and mortality of stage I non-small-cell lung cancer (NSCLC) patients.
METHODS: We carried out a National Cancer Institute (NCI) Intergroup phase III trial (NCI #I91-0001) with 1166 patients with pathologic stage I NSCLC (6 weeks to 3 years from definitive resection and no prior radiotherapy or chemotherapy). …
Authors
Lippman SM; Lee JJ; Karp DD; Vokes EE; Benner SE; Goodman GE; Khuri FR; Marks R; Winn RJ; Fry W
Journal
Journal of the National Cancer Institute, Vol. 93, No. 8, pp. 605–618
Publisher
Oxford University Press (OUP)
Publication Date
April 18, 2001
DOI
10.1093/jnci/93.8.605
ISSN
0027-8874